surmount 5 tirzepatide SURMOUNT-5 (NCT05822830) was a multi-center, randomized, open-label, phase 3b trial evaluating the efficacy and safety of #Zepbound® (tirzepatide) compared with #Wegovy® (semaglutide, similar to full dose #ozempic) in adults with obesity + SURMOUNT‐1 study design. This is

dose-response characterisation of GHS-R1a across multiple receptor-mediated outcomes simultaneously

High plasma levels of LDL, remnants and possibly Lp(a) promote accumulation of inflammatory cells, including foam cells, enhancing atherosclerotic plaque formation

The oak wood intervention also resulted in significant improvement in the liver enzymes AST and ALT, and in the liver fibrosis index, compared to the standard management group

These medications are generally recommended for individuals who are overweight or obese, especially if they have additional health risks like type 2 diabetes or metabolic syndrome

In compliance with the JTI standards More: SWI swissinfo.ch certified by the Journalism Trust Initiative You can find an overview of ongoing debates with our journalists here

MAIT cell inhibition promotes liver fibrosis regression via macrophage phenotype reprogramming